Nannini S, Sieffert C, McGown A, Gao XY, Jarvis A, Kostakis GE, Galvacsi A, Kallay C, Moraru R, Baud MG, Mandel S, Balourdas DI, Joerger AC, Orvain C, Peschard S, Nion A, Mellitzer G, Lottiaux S, Spencer J, Gross I, Gaiddon C

J Enzyme Inhib Med Chem. 2026 12;41(1):2638836

The unfolded protein response-glutathione metabolism axis: A novel target of a cycloruthenated complexes bypassing tumor resistance mechanisms.

Riegel G, Orvain C, Recberlik S, Spaety ME, Poschet G, Venkatasamy A, Yamamoto M, Nomura S, Tsukamoto T, Masson M, Gross I, Le Lagadec R, Mellitzer G, Gaiddon C

Cancer Lett. 2024 01 28;:216671

Morpho-functional analysis of patient-derived xenografts reveals differential impact of gastric cancer and chemotherapy on the tumor ecosystem, affecting immune check point, metabolism, and sarcopenia.

Venkatasamy A, Guerin E, Reichardt W, Devignot V, Chenard MP, Miguet L, Romain B, Jung AC, Gross I, Gaiddon C, Mellitzer G

Gastric Cancer. 2022 12 19;:

Anti-tumor effects of P-LPK-CPT, a peptide-camptothecin conjugate, in colorectal cancer.

Hou L, Hou Y, Liang Y, Chen B, Zhang X, Wang Y, Zhou K, Zhong T, Long B, Pang W, Wang L, Han X, Li L, Xu C, Gross I, Gaiddon C, Fu W, Yao H, Meng X

Commun Biol. 2022 11 14;5(1):1248

CDX2 controls genes involved in the metabolism of 5-fluorouracil and is associated with reduced efficacy of chemotherapy in colorectal cancer.

Delhorme JB, Bersuder E, Terciolo C, Vlami O, Chenard MP, Martin E, Rohr S, Brigand C, Duluc I, Freund JN, Gross I

Biomed Pharmacother. 2022 Jan 17;147:112630

Mesalazine initiates an anti-oncogenic β-catenin / MUCDHL negative feed-back loop in colon cancer cells by cell-specific mechanisms.

Bersuder E, Terciolo C, Lechevrel M, Martin E, Quesnelle C, Freund JN, Reimund JM, Gross I

Biomed Pharmacother. 2021 Dec 17;146:112543

Bypassing the Resistance Mechanisms of the Tumor Ecosystem by Targeting the Endoplasmic Reticulum Stress Pathway Using Ruthenium- and Osmium-Based Organometallic Compounds: An Exciting Long-Term Collaboration with Dr. Michel Pfeffer.

Gaiddon C, Gross I, Meng X, Sidhoum M, Mellitzer G, Romain B, Delhorme JB, Venkatasamy A, Jung AC, Pfeffer M

Molecules. 2021 Sep 4;26(17):

CDX2 inducible microRNAs sustain colon cancer by targeting multiple DNA damage response pathway factors.

Priya S, Kaur E, Kulshrestha S, Pandit A, Gross I, Kumar N, Agarwal H, Khan A, Shyam R, Bhagat P, Prabhu JS, Nagarajan P, Deo SVS, Bajaj A, Freund JN, Mukhopadhyay A, Sengupta S

J Cell Sci. 2021 Aug 1;134(15):

CDX2 inducible microRNAs sustain colon cancer by targeting multiple DNA damage response pathway factors.

Priya S, Kaur E, Kulshrestha S, Pandit A, Gross I, Kumar N, Agarwal H, Khan A, Shyam R, Bhagat P, Prabhu JS, Nagarajan P, Deo SVS, Bajaj A, Freund JN, Mukhopadhyay A, Sengupta S

J Cell Sci. 2021 Jul 19;:

CDX2 regulates ACE expression in blood development and leukemia cells.

El Omar R, Julien E, Biasch K, Guffroy B, Lioure B, Vallat L, Gross I, Domon-Dell C, Lanza F, Gachet C, Negroni M, Freund JN, Tavian M

Blood Adv. 2021 Apr 13;5(7):2012-2016

The atypical cadherin MUCDHL antagonizes colon cancer formation and inhibits oncogenic signaling through multiple mechanisms.

Beck M, Baranger M, Moufok-Sadoun A, Bersuder E, Hinkel I, Mellitzer G, Martin E, Marisa L, Duluc I, de Reynies A, Gaiddon C, Freund JN, Gross I

Oncogene. 2020 Nov 13;:

Dichloroacetate restores colorectal cancer chemosensitivity through the p53/miR-149-3p/PDK2-mediated glucose metabolic pathway.

Liang Y, Hou L, Li L, Li L, Zhu L, Wang Y, Huang X, Hou Y, Zhu D, Zou H, Gu Y, Weng X, Wang Y, Li Y, Wu T, Yao M, Gross I, Gaiddon C, Luo M, Wang J, Meng X

Oncogene. 2019 Oct 9;:

Fine-tuning and autoregulation of the intestinal determinant and tumor suppressor homeobox gene CDX2 by alternative splicing.

Balbinot C, Vanier M, Armant O, Nair A, Penichon J, Soret C, Martin E, Saandi T, Reimund JM, Deschamps J, Beck F, Domon-Dell C, Gross I, Duluc I, Freund JN

Cell Death Differ.. 2017 Sep;:

Prognostic factors of hemorrhagic complications after oxaliplatin-based hyperthermic intraperitoneal chemotherapy: Toward routine preoperative dosage of Von Willebrand factor?

Delhorme JB, Sattler L, Severac F, Triki E, Gross I, Romain B, Rohr S, Grunebaum L, Brigand C

Eur J Surg Oncol. 2017 Feb;:

The tumor suppressor CDX2 opposes pro-metastatic biomechanical modifications of colon cancer cells through organization of the actin cytoskeleton.

Platet N, Hinkel I, Richert L, Murdamoothoo D, Moufok-Sadoun A, Vanier M, Lavalle P, Gaiddon C, Vautier D, Freund JN, Gross I

Cancer Lett.. 2017 Feb;386:57-64

Distinct mechanisms for opposite functions of homeoproteins Cdx2 and HoxB7 in double-strand break DNA repair in colon cancer cells.

Soret C, Martin E, Duluc I, Dantzer F, Vanier M, Gross I, Freund JN, Domon-Dell C

Cancer Lett.. 2016 May;374(2):208-15

Transcriptional activator TAp63 is upregulated in muscular atrophy during ALS and induces the pro-atrophic ubiquitin ligase Trim63.

von Grabowiecki Y, Abreu P, Blanchard O, Palamiuc L, Benosman S, Mériaux S, Devignot V, Gross I, Mellitzer G, Gonzalez de Aguilar JL, Gaiddon C

Elife. 2016 Feb;5:

Extending the functions of the homeotic transcription factor Cdx2 in the digestive system through nontranscriptional activities.

Freund JN, Duluc I, Reimund JM, Gross I, Domon-Dell C

World J Gastroenterol. 2015 Feb 7;21(5):1436-43

Transcriptional regulation of the intestinal nuclear bile acid farnesoid X receptor (FXR) by the caudal-related homeobox 2 (CDX2).

Modica S, Cariello M, Morgano A, Gross I, Vegliante MC, Murzilli S, Salvatore L, Freund JN, Sabba C, Moschetta A

J Biol Chem. 2014 Oct 10;289(41):28421-32

Gastric intrinsic factor deficiency with combined GIF heterozygous mutations and FUT2 secretor variant.

Chery C, Hehn A, Mrabet N, Oussalah A, Jeannesson E, Besseau C, Alberto JM, Gross I, Josse T, Gerard P, Gueant-Rodriguez RM, Freund JN, Devignes J, Bourgaud F, Peyrin-Biroulet L, Feillet F, Gueant JL

Biochimie. 2013 May;95(5):995-1001